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Objectives: To examine factors affecting the failure rate to obtain a result from (cf) DNA testing 
of maternal blood for fetal trisomies 21, 18 and 13 in singleton and twin pregnancies in the first 
trimester of pregnancy. 
 
Methods: This was a prospective study in 23,495 singleton and 928 twin pregnancies 
undergoing screening for fetal trisomies by targeted cfDNA testing at 10+0-14+1 weeks’ gestation. 
Multivariate regression analysis was used to determine significant predictors of failure to obtain 
a result after first sampling. 
 
Results: There was no result from cfDNA testing after first sampling in 3.4% (798/23,495) of 
singletons, 11.3% (91/806) of DC twins and in 4.9% (6/122) of MC twins. Multivariate logistic 
regression analysis demonstrated that the risk of test failure first, increased with increasing 
maternal age (odds ratio (OR) 1.02; 95% confidence interval (CI) 1.01, 1.04) and weight (OR 
1.05; 95% CI 1.04, 1.05), decreasing gestational age (OR 0.85; 95% CI 0.79, 0.91) and serum 
PAPP-A (OR 0.56; 95% CI 0.49, 0.64) and free ß-hCG (OR 0.67; 95% CI 0.60, 0.74), second, 
was higher in women of Black  (OR 1.72; 95% CI 1.33, 2.20) and South Asian (OR 1.99; 95% CI 
1.56, 2.52) than White racial origin, in dichorionic twin (OR 1.75; 95% CI 1.34, 2.25) than 
singleton pregnancy and in in vitro fertilization (OR 3.82; 95% CI 3.19, 4.55) than natural 
conception and third, was lower in parous (OR 0.63; 95% CI 0.55, 0.74) than nulliparous 
women.  
 
Conclusions: Maternal age, weight, racial origin and parity, gestational age, dichorionicity, 
method of conception and serum levels of free ß-hCG and PAPP-A are independent predictors 
of cfDNA test failure. The risk of test failure is higher in dichorionic twin than in singleton 
pregnancies, mainly because a higher proportion of twins are conceived by in vitro fertilization 
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In singleton pregnancies, cell-free (cf) DNA analysis of maternal blood provides effective 
screening for trisomies 21, 18 and 13.1 A meta-analysis of clinical validation and implementation 
studies has reported that the performance of cfDNA testing for trisomy 21 in twin pregnancies is 
similar to that in singleton pregnancies; the number of cases of trisomies 18 and 13 was too 
small for accurate assessment of predictive performance of the test for these trisomies.1 
 
One issue with cfDNA testing as a method of screening for aneuploidies is failure to provide a 
result. There are essentially three reasons for such failure. First, problems with blood collection 
and transportation of the samples to the laboratory, including inadequate blood volume, 
hemolysis, incorrect labelling of tubes and delay in arrival to the laboratory. Second, low fetal 
fraction, usually below 4%, and thirdly, assay failure for a variety of reasons, including failed 
DNA extraction, amplification and sequencing.2 The most common reason for test failure is low 
fetal fraction and the main contributors to low fetal fraction in both singleton and twin 
pregnancies are first, small placental mass, reflected in early gestational age and low serum 
free -hCG and PAPP-A, because the likely source of fetal cfDNA in maternal plasma is dying 
cells in the placenta, and second, high maternal weight, which could be attributed to a dilutional 
effect.3-6 Impaired placentation has also been considered to be the likely reason for the low fetal 
fraction and high failure rate in conceptions by in vitro fertilization.6-9 In twin pregnancies the 
targeted approach to cfDNA testing with estimation of fetal fraction from each twin, which aims 
to minimize the risk of providing false negative results by ensuring that the lower of the two is at 
least 4%, is associated with a higher failure rate than methods which do not measure fetal 
fraction or ignore assessment of the contribution of each fetus.  
 
The objective of this expanded series of 23,495 singleton and 928 twin pregnancies undergoing 
screening for fetal trisomies by targeted cfDNA testing at 10+0-14+1 weeks’ gestation was to 
explore further the relationship between failure rate and maternal and pregnancy characteristics. 
The study also explores potential differences in failure rate between two methods of targeted 




Study design and participants  
 
The data for the study were derived from prospective screening for trisomies 21, 18 and 13 in 
twin pregnancies at 10+0-14+1 weeks’ gestation. Two populations were included; first self-
referred women to the Fetal Medicine Centre in London, which is a private clinic2,10 and second, 
women selected for the cfDNA test after routine first-trimester combined testing in one of two 
National Health Service hospitals in England.11,12 The patients were examined between October 
2012 and January 2018. The study was approved by the National Research Ethics Committee 
(REC reference 13/LO/0885, 19/HRA/0576).  
 
We recorded maternal characteristics and medical history, including maternal age, racial origin 
(White, Black, South Asian, East Asian and mixed), method of conception (natural or assisted 
conception requiring the use of ovulation drugs or in-vitro fertilization), cigarette smoking during 
pregnancy (yes or no) and parity (parous or nulliparous if no previous pregnancy at or after 24 
weeks’ gestation). We also measured maternal weight and height. In all cases free ß-hCG and 
PAPP-A were measured at 10+0-13+6 weeks (DELFIA Xpress system, PerkinElmer Life and 
Analytical Sciences, Waltham, USA, or Kryptor, Thermo Scientific, Berlin, Germany). An 
ultrasound scan was carried out at 11+0-13+6 weeks to determine gestational age from the 
measurement of the fetal crown-rump length (CRL),13 diagnose any major fetal abnormalities 
and measure fetal nuchal translucency (NT) thickness. In twin pregnancies, gestational age was 
determined from the CRL of the larger fetus and chorionicity was determined by examining the 
junction of the intertwin membrane with the placenta.14 The measured free ß-hCG and PAPP-A 
were converted into multiple of the median (MoM) for gestational age adjusted for maternal 
weight, racial origin, smoking status, method of conception, parity, chorionicity and machine for 
the assays.7  
 
Women provided written informed consent and maternal blood (20 mL) was sent via courier to 
the USA for cfDNA testing (Harmony® prenatal test, Roche/Ariosa Diagnostics, Inc., San Jose, 
CA, USA).15,16 Harmony® uses DANSR assays targeting sequences on chromosomes 13, 18, 
and 21 for chromosome quantitation and single nucleotide polymorphisms on chromosomes 1 
to 12 for fetal fraction measurement. Products of the DANSR assays can be quantified using 
either next-generation sequencing (chromosome selective sequencing) or a custom microarray; 
both were used during the course of this study. The data are analysed with the fetal fraction 
optimized FORTE algorithm, which calculates probability scores for fetal trisomy, with greater 
than 1% considered to be high probability. In cases where the cfDNA test did not provide results 
the parents were offered repeat testing or to rely on the results of the combined test in deciding 
whether to have an invasive test or not. In cases with a high-risk result from the cfDNA test, the 
parents were advised to consider having invasive fetal karyotyping before deciding on the 
further management of their pregnancy.  
 
Patient characteristics, results of the investigations and pregnancy outcome were recorded in a 
database. The outcomes were divided into first, trisomy 21, 18 or 13 if the karyotype of chorionic 
villi, amniotic fluid or neonatal blood demonstrated the relevant trisomy in one or both fetuses, 
second, no trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood 
was normal or both neonates were phenotypically normal, third, no known karyotype in both 
fetuses because the pregnancies resulted in termination or embryo reduction, miscarriage or 
stillbirth and no karyotyping of fetal tissue was carried out, and fourth, outcome unknown 




Descriptive data were presented in median and interquartile range (IQR) for continuous 
variables and in numbers and percentages for categorical variables. Comparisons between 
groups were performed using the Mann–Whitney U-test for continuous variables and the χ2-test 
or Fisher’s exact test for categorical variables. In the combined data of singleton and twin 
pregnancies multivariate logistic regression analysis was used to determine which of the factors 
amongst maternal age, weight, height, racial origin, smoking status, parity, method of 
conception, gestational age at sampling, serum PAPP-A and free ß-hCG MoM, fetal karyotype, 
type of pregnancy (singleton, DC and MC twins) and type of targeted analysis (sequencing and 
microarray) were significant predictors of failed cfDNA test result after first sampling. Variance 
inflation factor (VIF), which represents the factor by which the variance is inflated, was used to 
assess multicollinearity; VIF values > 4 require further investigation, whereas VIF values 
exceeding 10, which are signs of serious multicollinearity, require correction. 
 
We conducted statistical analyses using package R software.17 VIFs were calculated using the 






A total of 24,974 singleton pregnancies had cfDNA testing, but 1,479 (5.9%) of these were 
excluded from further analysis either because the pregnancies ended in termination, 
miscarriage or stillbirth with no known karyotype (n=356) or they were lost to follow up 
(n=1,123). In the 23,495 cases included in the study, there were 324 with trisomy 21, 104 with 
trisomy 18, 28 of trisomy 13 and 23,039 without trisomy 21, 18 or 13. 
 
A total of 991 twin pregnancies had cfDNA testing, but 63 (6.4%) of these were excluded from 
further analysis either because the pregnancies ended in termination, miscarriage or stillbirth 
with no known karyotype (n=45) or they were lost to follow up (n=18). In the 928 cases included 
in the study, 806 (86.9%) were dichorionic and 122 (13.1%) were monochorionic. The 928 twin 
pregnancies included 14 with trisomy 21, 7 with trisomy 18, 1 of trisomy 13 and 906 without 
trisomy 21, 18 or 13; all trisomic cases were in the DC pregnancies and in all cases one fetus 
was trisomic and the cotwin was non-trisomic. 
 
Maternal and pregnancy characteristics of the 23,495 singleton and 928 twin pregnancies 
included in the study are summarized in Table 1. cfDNA testing was done by means of 
sequencing in 9,440 of singleton pregnancies and 313 of the twin pregnancies and by 
microarray in 14,055 of the singleton pregnancies and 615 of the twin pregnancies. 
 
Factors affecting cfDNA test failure after first sampling 
 
There was no result from cfDNA testing after first sampling in 3.4% (798/23,495) of singletons 
(433 because of insufficient fetal cfDNA and 365 because the sample did not meet thresholds 
for quality control), in 11.3% (91/806) of DC twins (70 because of insufficient fetal cfDNA and 21 
because the sample did not meet thresholds for quality control) and in 4.9% (6/122) of MC twins 
(5 because of insufficient fetal cfDNA and 1 because the sample did not meet thresholds for 
quality control). 
 
In 614 of the 798 singleton pregnancies with no result after first sampling the cfDNA test was 
repeated 1-2 weeks later and in 413 (67.3%) cases a result was obtained. In 82 of the 91 
dichorionic twin pregnancies with no result after first sampling repeat testing provided a result in 
45 (54.9%) cases. In 5 of the 6 monochorionic twin pregnancies with no result after first 
sampling repeat testing provided a result in all cases. 
 
In the combined data from singleton and twin pregnancies, multivariate logistic regression 
analysis demonstrated that the risk of test failure first, increased with increasing maternal age 
and weight, decreasing gestational age and serum PAPP-A and free ß-hCG, second, was 
higher in women of Black and South Asian than White racial origin, in dichorionic twin than 
singleton pregnancy and in in vitro fertilization than natural conception and third, was lower in 
parous than nulliparous women; there was no significant contribution from fetal karyotype or 
method of cfDNA testing (Table 2). VIFs for all variables included in the regression analysis 




Principal findings of the study  
 
In this study of cfDNA testing in singleton and twin pregnancies at 10-14 weeks’ gestation, we 
found that the most important contributor to cfDNA test failure after first sampling is conception 
by in vitro fertilization, which by comparison to natural conception, increases the risk by 3.8 
times. Other contributors to test failure are Black or South Asian racial origin, which by 
comparison to White origin, increase the risk by 2.0 and 1.7 times, respectively, and 
dichorionicity, which by comparison to singleton pregnancies, increases the risk by 1.7 times. 
The risk of test failure increases by about 5% with each additional kilogram in maternal weight 
and by about 2% with each additional year in maternal age. In parous women the risk of test 
failure is 37% lower than in nulliparous women and other protective factors against test failure 
are increasing gestational age and increasing serum PAPP-A and free ß-hCG. Test failure is 
unrelated to method used for cfDNA analysis and fetal karyotype, once serum PAPP-A and free 
ß-hCG are taken into account. 
 
Test failure after first sampling in dichorionic twins was 3.3 times higher than in singletons 
(11.3% vs. 3.4%), but to a great extent this excess failure rate can be attributed to the fact that a 
considerably higher proportion of twins were conceived by in vitro fertilization (59.8% vs. 10.4%) 
and more women were nulliparous (61.3% vs. 44.3%).  
 
Comparison to findings in previous studies 
 
The data presented in this paper were derived from the use of the Harmony® prenatal test and 
the results may not be applicable to other methods of cfDNA testing. In a previous meta-
analysis on performance of screening for aneuploidies by cfDNA testing we noted a wide range 
in failure rates between studies and it was not possible to draw conclusions on the possible 
relationship between the no result rate and the method used for the analysis of the samples.1  
 
The main cause of cfDNA test failure is reduced fetal fraction and many previous studies have 
reported an inverse association between fetal fraction and maternal weight, which could be 
attributed to a dilutional effect and / or enhanced turnover of adipocytes and a secondary 
increase in maternal cfDNA in maternal plasma.3-6,19-22 Similarly, our finding of an increased 
cfDNA test failure with decreasing gestational age, PAPP-A and free β-hCG MoMs is consistent 
with the findings from previous studies and it is probably related to smaller placental mass and 
therefore decreased placental cfDNA in maternal blood.4,13,19,23,24  
 
In our previous studies we also found that in pregnancies conceived by in vitro fertilization 
cfDNA test failure is increased,6,25 but another study on twin pregnancies analysed by a different 
cfDNA technique could not demonstrate such an association.26 Low fetal fraction in conceptions 
by in vitro fertilization could be the consequence of the associated impaired placentation; in 
such pregnancies the serum concentration of PAPP-A is decreased by 10-25%7-9 and the 
incidence of preeclampsia is increased.27,28 Two likely explanations for these different results 
are first, the significantly higher gestational age at sampling (median 16 weeks, range 10-35) in 
the study of Le Conte et al.,26 by comparison to our study (median 11 weeks, range 10-14) and 
second, the different method used for cfDNA analysis (massively parallel sequencing26 vs. 
targeted approach). It has been reported that the failure rate is lowest in methods based on 
massive parallel sequencing (1.58%), followed by chromosome selective sequencing (3.56%) 
and single-nucleotide polymorphism based analysis (6.39%).29 In our study two different 
methods for targeted cfDNA analysis were used (chromosome selective sequencing and 
microarray based analysis) and no differences were found between them in relation to test 
failure.  
 
In pregnancies with cfDNA test failure there is increased risk of fetal trisomies 18, 13 and 
triploidy, but not trisomy 21.6,29,30 In our study we also found a significantly higher risk of test 
failure in trisomies 18 and 13, but this association did not remain after adjusting for serum 
biomarkers; it is therefore likely that this association is mediated by the small placental mass 
related to these conditions, rather than the conditions themselves. 
 
Implications for clinical practice 
 
In a very high proportion of both singleton and twin pregnancies cfDNA testing will provide a 
result after first sampling. In pregnancies with cfDNA test failure repeat sampling will provide a 
result in half to two-thirds of cases. Most women at highest risk of test failure (advanced age, 
obese, Black nulliparous women with dichorionic twin pregnancy conceived by in vitro 
fertilization) are still likely to obtain a result from cfDNA testing but they should have pretest 
counselling regarding the possibility of a failed test. The decision in favor or against invasive 
testing in the management of pregnancies with a failed result, should depend on the risk from 
prior screening and the results of detailed ultrasound examination looking for specific features of 




Maternal age, weight, racial origin and parity, gestational age, dichorionicity, method of 
conception and serum levels of free ß-hCG and PAPP-A are independent predictors of cfDNA 
test failure. The risk of test failure is higher in dichorionic twin than in singleton pregnancies, 
mainly because a higher proportion of twins are conceived by in vitro fertilization and more of 
the women are nulliparous. 
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Table 1. Maternal and pregnancy characteristics of the study population. 
 







Maternal age in years, median (IQR) 36.1 (32.9, 39.1) 37.2 (34.2, 9.6)* 36.9 (34.0, 39.2) 
Maternal weight in kg, median (IQR) 64.0 (58.0, 73.0) 65.0 (58.6, 75.0)* 63.0 (56.1, 71.7) 
Maternal height in cm, median (IQR) 165 (161, 170) 167 (162, 170)* 165 (160, 170) 
Racial origin    
   White, n (%) 19,226 (81.8) 669 (83.0)* 100 (82.0) 
   Black, n (%) 1,412 (6.0) 51 (6.3) 3 (2.5) 
   South Asian, n (%) 1,525 (6.5) 52 (6.4) 8 (6.6) 
   East Asian, n (%) 895 (3.8) 24 (3.0) 7 (5.7) 
   Mixed, n (%) 437 (1.9) 10 (1.2) 4 (3.3) 
Parity    
   Nulliparous, n (%) 10,402 (44.3) 494 (61.3)* 59 (48.4)* 
   Parous, n (%) 13,093 (55.7) 312 (38.7)* 63 (51.6)* 
Cigarette smoker, n (%) 640 (2.7) 10 (1.2)* 1 (0.08) 
Conception    
   Natural, n (%) 20,978 (89.3) 310 (38.5)* 85 (69.7)* 
   Ovulation induction, n (%) 79 (0.3) 14 (1.7)* 2 (1.6) 
   In vitro fertilization, n (%) 2,438 (10.4) 482 (59.8)* 35 (28.7) 
Gestation at sampling in weeks, median (IQR) 11.9 (10.7, 12.9) 11.9 (10.6, 12.7) 12.0 (10.7, 13.0) 
Serum PAPP-A MoM, median (IQR) 0.89 (0.58, 1.32) 1.04 (0.75, 1.46)* 0.99 (0.72, 1.48)* 
Serum ß-hCG MoM, median (IQR) 1.11 (0.72, 1.73) 1.01 (0.72, 1.52)* 1.02 (0.65, 1.56)* 
Method of cfDNA test    
   Sequencing 9,440 (40.2) 269 (33.4)* 44 (36.1) 
   Microarray 14,055 (59.8) 537 (66.6)* 78 (63.9) 
No result after first cfDNA testing 798 (3.4) 91 (11.3) 6 (4.9) 
 
DC = dichorionic; MC = monochorionic; IQR = interquartile range; MoM = multiple of the median 
 
Comparisons between groups were performed using Mann–Whitney U-test for continuous variables 





Table 2. Univariate and multivariate logistic regression analysis demonstrating factors from maternal and 
pregnancy characteristics providing significant contribution to prediction of failed cfDNA testing. 
 
CI = confidence interval; MoM = multiple of the median 
Independent variable 
Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Intercept   0.008 (0.003, 0.022) <0.0001 
Age in years 1.048 (1.033, 1.064) <0.0001 1.024 (1.009, 1.041) 0.002 
Weight in kg 1.041 (1.037, 1.044) <0.0001 1.049 (1.045, 1.053) <0.0001 
Height in cm 1.001 (0.991, 1.011) 0.841 -  
Racial origin     
   White  (Reference)    
   Black 1.942 (1.544, 2.415) <0.0001 1.716 (1.328, 2.196) <0.0001 
   South Asian 1.685 (1.333, 2.105) <0.0001 1.992 (1.557, 2.521) <0.0001 
   East Asian 0.665 (0.415, 1.005) 0.069 -  
   Mixed 1.261 (0.765, 1.952) 0.330 -  
Smoking 1.187 (0.790, 1.710) 0.382 -  
Conception      
   Natural (Reference)    
   Ovulation induction 0.789 (0.130, 2.500) 0.741 -  
   In vitro fertilization 4.550 (3.944, 5.242) <0.0001 3.815 (3.195, 4.551 <0.0001 
Parity     
   Nulliparity (Reference)    
   Multiparity 0.617 (0.539, 0.706) <0.0001 0.635 (0.546, 0.737) <0.0001 
Gestational age 0.872 (0.824, 0.923) <0.0001 0.847 (0.792, 0.906) <0.0001 
Serum PAPP-A MoM 0.576 (0.504, 0.656) <0.0001 0.563 (0.489, 0.645) <0.0001 
Serum free ß-hCG MoM 0.606 (0.547, 0.669) <0.0001 0.668 (0.601, 0.739) <0.0001 
Fetal karyotype     
   Non-trisomic (Reference)    
   Trisomy 21 0.975 (0.516, 1.663) 0.932 -  
   Trisomy 18 or 13 2.484 (1.298, 4.316) 0.003 1.133 (0.565, 2.090) 0.704 
Pregnancy type     
    Singleton  (Reference)    
    Dichorionic twins 3.620 (2.862, 4.529) <0.0001 1.748 (1.343 (2.255) <0.0001 
    Monochorionic twins 1.471 (0.574, 3.072) 0.358 -  
Method of cfDNA test     
   Sequencing (Reference)    
 Microarray 1.083 (0.945, 1.244) 0.254 -  
